Select a company

Go

Company Stage

  • Private (seed)
  • Private (post-seed)
  • Quoted

Sector

  • Energy and Renewables
  • IT & Communications
  • Chemicals & Materials
  • Biotech
  • Healthcare

University

  • University of Bath
  • University of Bristol
  • University of Cardiff
  • University of Glasgow
  • University of Leeds
  • King's College London
  • Queen Mary, University of London
  • University of Manchester
  • University of Nottingham
  • University of Oxford
  • University of Sheffield
  • University of Southampton
  • University of Surrey
  • Swansea University
  • University of York
  • Other

Stakeholder

  • IP Group
  • IP Venture Fund
  • Top 10 Holdings
    by value
Medical Equipment & Supplies

University: Bristol

Company Stage: Private (post-seed)

Website: http://www.azellonctx.com/

Azellon Cell Therapeutics

Azellon is a spin-out company from The University of Bristol focused on the research, development and commercialisation of an adult autologous (patient's own) stem cell technology which in vitro (tissue culture) has shown great promise for the healing of meniscal tears.

As at 31 Dec 2012

IP Group holding

 

25.5%

Holding represents undiluted beneficial equity interest excluding debt

Related news

14 Nov 2011

There is currently no news available.

More portfolio news